Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on On Assignment

Related ASGN
Earnings Scheduled For February 14, 2017
Deutsche Bank Initiates On Assignment Shares With A Buy Rating

In a report published Friday, BMO Capital Markets reiterated its Outperform rating on On Assignment (NYSE: ASGN), and slightly raised its price target from $23.00 to $24.00.

BMO Capital noted, “The ‘upside surprise' (at least versus our estimates) was mainly margin driven, as revenues of $388.3 million was just above $382-$388 million guidance, while adjusted EBITDA margins increased to 11.7% from 11.2% in 3Q11 – well above our 11.1% estimate and the highest since 2001. ASGN is dominated by its technology offerings (roughly 75% of revenues), which grew y/y (pro forma) in the high teens, by our estimates – likely faster than the market. Its healthcare and physician offerings (15% of revenues) are also showing solid growth as those sectors come back to life. While Life Sciences (10% of revenues) is struggling owing to a challenging environment, ASGN's diversification strategy is helping to offset that. While the company is not immune from the slower growth facing the sector, we still believe ASGN has and will continue to take share.”

On Assignment closed on Thursday at $19.48.

Latest Ratings for ASGN

Nov 2017BMO CapitalMaintainsOutperform
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017Deutsche BankMaintainsBuy

View More Analyst Ratings for ASGN
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (ASGN)

View Comments and Join the Discussion!